Cartilage Repair/Regeneration Market Analysis By Treatment Modality (Cell-Based, Non-Cell-Based), By Application (Hyaline Cartilage, Fibrocartilage), By Treatment Type (Palliative, Intrinsic Repair Stimulus), By Site (Knee Cartilage Repair), And Segment Forecasts, 2014 - 2025

The global cartilage repair/regeneration market is expected to reach USD 6.7 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness lucrative growth over the forecast period, owing to increasing prevalence of bone & joint disorders, such as Osteoarthritis (OA), rising geriatric population, and surge in number of accidents & related injuries across the globe.
Increasing number of road accidents worldwide are causing bone and joint injuries, which is anticipated to fuel the demand for cartilage repair products over the forecast period. For instance, as per data published by the World Health Organization (WHO) in November 2016, approximately 1.25 million people die each year in road accidents worldwide, owing to the influence of alcohol & reckless driving, use of mobile phone, and other associated factors such as bad weather conditions & improper road construction.
Around 30.0 million children and adolescents participate in youth sports in the U.S each year. This increase in sports activity increases incidents of injuries in athletes, which in turn propels demand for cartilage repair products. According to research data by the American Orthopaedic Society for Sports Medicine, over 3.5 million athletes receive medical treatment due to sports injuries each year.
Further Key Findings From the Study Suggest:
‧ The cell-based segment held a profitable revenue share in 2016 and is anticipated to grow at a significant rate over the forecast period owing to rising preference for autologous chondrocyte transplantation for surgical treatment of damaged articular cartilage (chondral and osteochondral lesions)
‧ The hyaline cartilage segment is anticipated to witness the fastest growth during the forecast period due to high susceptibility of damage to hyaline cartilage in case cartilage-related injuries and increase in sport injuries
‧ Owing to the extensive use of microfracture techniques during cartilage repair surgeries, the intrinsic repair stimulus segment dominated the market in 2016
‧ Increasing prevalence of OA and rise in accident-related injuries are anticipated to support the growth of knee cartilage repair segment
‧ North America is expected to dominate the cartilage repair market during the forecast period, owing to the rising prevalence of bone & joint disorders, increase in number of accidents & injuries, and growing geriatric population in the region are expected to spur the cartilage regeneration market growth.
‧ Some of the key players of cartilage repair market are Zimmer Biomet; Stryker Corporation; DePuy Synthes; Smith & Nephew plc; Vericel Corporation; Osiris Therapeutics Inc.; B. Braun Melsungen AG; Anika Therapeutics, Inc.; Arthrex, Inc.; and Collagen Solutions Plc.

Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.1.1. Purchased database
1.1.2. GVR’s internal database
1.2. Data Analysis
1.3. Market Formulation & Validation
1.4. Primary Research
1.4.1. List of primary sources
1.5. Approaches for Market Estimation
1.5.1. Approach 1: Commodity flow & bottom-up approach
1.5.2. Approach 2: Top-down and parent market analysis
Chapter 2. Executive Summary
2.1. Market Snapshot, 2016
Chapter 3. Cartilage Repair/Regeneration Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.3. Market Restraint Analysis
3.4. Penetration & Growth Prospect Mapping
3.5. SWOT Analysis, by Factor
3.5.1. Political
3.5.2. Economic
3.5.3. Technological
3.6. Industry Analysis - Porter’s
Chapter 4. Cartilage Repair/Regeneration Market: Treatment Modality Estimates & Trend Analysis
4.1. Treatment Modality Movement Analysis & Market Share, 2016 & 2025
4.2. Market Size Estimates & Forecasts and Trend Analyses, 2014 to 2025 for the following treatment modality:
4.2.1. Cell-based
4.2.1.1. Chondrocyte transplantation
4.2.1.1.1. Chondrocyte transplantation market estimates and forecasts, 2014 to 2025
4.2.1.2. Growth factor pharmacology
4.2.1.2.1. Growth factor technology market estimates and forecasts, 2014 to 2025
4.2.2. Non-Cell-based
4.2.2.1. Tissue scaffolds
4.2.2.1.1. Tissue scaffolds market estimates and forecasts, 2014 to 2025
4.2.2.2. Cell-free composites
4.2.2.2.1. Cell-free composites market estimates and forecasts, 2014 to 2025
Chapter 5. Cartilage Repair/Regeneration Market: Application Estimates & Trend Analysis
5.1. Application Movement Analysis & Market Share, 2016 & 2025
5.2. Market Size Estimates & Forecasts for the following application:
5.2.1. Hyaline cartilage
5.2.1.1. Hyaline cartilage market estimates and forecasts, 2014 to 2025
5.2.2. Fibrocartilage
5.2.2.1. Fibrocartilage market estimates and forecasts, 2014 to 2025
Chapter 6. Cartilage Repair/Regeneration Market: Treatment Type Estimates & Trend Analysis
6.1. Treatment Type Analysis & Market Share, 2016 & 2025
6.2. Market Size Estimates & Forecasts for the following treatment type:
6.2.1. Palliative
6.2.1.1. Viscosupplementation
6.2.1.1.1. Viscosupplementation market estimates and forecasts, 2014 to 2025
6.2.1.2. Debridement & Lavage
6.2.1.2.1. Debridement & lavage market estimates and forecasts, 2014 to 2025
6.2.2. Intrinsic repair stimulus
6.2.2.1. Intrinsic repair stimulus market estimates and forecasts, 2014 to 2025
Chapter 7. Cartilage Repair/Regeneration Market: Site Estimates & Trend Analysis
7.1. Site Movement Analysis & Market Share, 2016 & 2025
7.2. Market Size Estimates & Forecasts for the following site:
7.2.1. Knee cartilage repair
7.2.1.1. Knee cartilage repair market estimates and forecasts, 2014 to 2025
7.2.2. Other
7.2.2.1. Other market estimates and forecasts, 2014 to 2025
Chapter 8. Cartilage Repair/Regeneration Market: Regional Estimates & Trend Analysis
8.1. Regional Movement Analysis & Market Share, 2016 & 2025
8.2. North America
8.2.1. U.S.
8.2.1.1. U.S. revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.2.1.2. U.S. revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.2.1.3. U.S. revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.2.1.4. U.S. revenue estimates and forecasts, by technique 2014 - 2025 (USD Million)
8.2.2. Canada
8.2.2.1. Canada revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.2.2.2. Canada revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.2.2.3. Canada revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.2.2.4. Canada revenue estimates and forecasts, by site 2014 - 2025 (USD Million)
8.3. Europe
8.3.1. UK
8.3.1.1. UK revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.3.1.2. UK revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.3.1.3. UK revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.3.1.4. UK revenue estimates and forecasts, by site 2014 - 2025 (USD Million)
8.3.2. Germany
8.3.2.1. Germany revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.3.2.2. Germany revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.3.2.3. Germany revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.3.2.4. Germany revenue estimates and forecasts, by site 2014 - 2025 (USD Million)
8.4. Asia Pacific
8.4.1. Japan
8.4.1.1. Japan revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.4.1.2. Japan revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.4.1.3. Japan revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.4.1.4. Japan revenue estimates and forecasts, by site 2014 - 2025 (USD Million)
8.4.2. China
8.4.2.1. China revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.4.2.2. China revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.4.2.3. China revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.4.2.4. China revenue estimates and forecasts, by site 2014 - 2025 (USD Million)
8.5. Latin America
8.5.1. Brazil
8.5.1.1. Brazil revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.5.1.2. Brazil revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.5.1.3. Brazil revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.5.1.4. Brazil revenue estimates and forecasts, by site 2014 - 2025 (USD Million)
8.5.2. Mexico
8.5.2.1. Mexico revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.5.2.2. Mexico revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.5.2.3. Mexico revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.5.2.4. Mexico revenue estimates and forecasts, by site 2014 - 2025 (USD Million)
8.6. MEA
8.6.1. South Africa
8.6.1.1. South Africa revenue estimates and forecasts, by treatment modality 2014 - 2025 (USD Million)
8.6.1.2. South Africa revenue estimates and forecasts, by application 2014 - 2025 (USD Million)
8.6.1.3. South Africa revenue estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
8.6.1.4. South Africa revenue estimates and forecasts, by site 2014 - 2025 (USD Million)
Chapter 9. Competitive Landscape
9.1. Strategy Framework
9.2. Company Profiles
9.2.1. Zimmer Biomet
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Stryker Corporation
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. Depuy Synthes
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. Smith & Nephew plc
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Vericel Corporation
9.2.5.1. Company overview
9.2.5.2. Financial Performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Osiris Therapeutics Inc.
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. B. Braun Melsungen AG
9.2.7.1. Company overview
9.2.7.2. Financial Performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Anika Therapeutics, Inc.
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Arthrex, Inc.
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Collagen Solutions Plc
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives